What are the efficacy and effects of brigatinib? What diseases does it have significant efficacy in treating?

Brigatinib (Brigatinib) is a targeted therapy drug that is a tyrosine kinase inhibitor (TKI). It is mainly used to treat non-small cell lung cancer (NSCLC) with positive ALK gene rearrangement. It inhibits the proliferation and metastasis of cancer cells by inhibiting the ALK (anaplastic lymphoma kinase) signaling pathway, thereby achieving the effect of inhibiting tumor growth. Brigatinib was initially approved for the treatment of patients with non-small cell lung cancer who have received first-line ALK-targeted therapy, especially those whose disease has progressed or developed drug resistance.

The efficacy of brigatinib has been confirmed in clinical studies. In a pivotal clinical trial called ALTA-1L, brigatinib demonstrated greater efficacy than traditional first-generation ALK inhibitors such as crizotinib. Studies have shown that brigatinib can significantly prolong progression-free survival (PFS) in patients with non-small cell lung cancer positive for ALK gene rearrangement, and is superior to crizotinib on multiple endpoints. In addition, brigatinib has strong efficacy in patients with different ALK mutations, including common resistance mutations such as G1202R mutation and F1174L mutation. Brigatinib provides an important treatment option for patients who develop resistance to crizotinib.

The efficacy of brigatinib is not limited to ALK mutated non-small cell lung cancer, but also shows potential in the treatment of other types of tumors. For example, brigatinib has also made some progress in personalized cancer treatment. Studies have found that brigatinib exhibits a certain inhibitory effect on some NTRK gene fusion-positive tumors. This makes it possible for brigatinib to become an effective therapeutic drug in some cancer patients with specific gene mutations, expanding its scope of indications in tumor treatment.

Compared with otherALK inhibitors, brigatinib has stronger penetrating power, especially for patients with non-small cell lung cancer with brain metastasis, its blood-brain barrier penetration is relatively strong. This means that brigatinib can better treat patients with brain metastases, who often face treatment difficulties due to insufficient blood-brain barrier penetration of traditional drugs. Therefore, brigatinib is particularly suitable for patients with non-small cell lung cancer who have brain metastases.

Side effects of brigatinib, although common, are controllable in most cases. Common side effects include diarrhea, fatigue, musculoskeletal pain, and hypertension. Diarrhea is one of the most common side effects of brigatinib and can usually be managed with medication adjustments or the use of antidiarrheal medications. In addition, brigatinib may cause pulmonary side effects such as pneumonia, so the patient's lung function needs to be closely monitored during treatment and corresponding measures need to be taken in a timely manner.

In general, brigatinib, as a second-generation ALK targeted drug, has shown strong efficacy in the treatment of patients with non-small cell lung cancer positive for ALK gene rearrangement, especially in patients with drug resistance or recurrence. It has important clinical significance. With the deepening of clinical application, brigatinib will not only provide new treatment options for patients with non-small cell lung cancer, but may also play an important role in the treatment of other related tumors.

Reference materials:https://www.alunbrig.com/